Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific MeetingData Support New Drug Application for neffy®, Currently Under Review with U.S. FDASAN DIEGO – November 10, 2022 - ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) (ARS or...
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO – November 8, 2022 -...
ARS Pharmaceuticals announces FDA acceptance of NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approvedSAN DIEGO – October 21, 2022 - ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application...
Silverback Therapeutics and ARS Pharmaceuticals Conference Call
Silverback Therapeutics and ARS Pharmaceuticals, Inc.Conference Call July 21, 2022 at 5:00 PM EDT Conference Call
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
Transaction to support potential commercialization of neffy™, ARS’s needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expectedCompanies to host conference call today, July 21, 2022, at 5:00 p.m. ET SEATTLE and SAN DIEGO – July 21, 2022 – Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS...